Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-04-26

Study Completion Date

2021-10-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to assess the efficacy and safety of XC8, film-coated tablets, 10 mg in comparison with placebo in patients with dry non-productive cough against acute respiratory infections, and to determine the dosing regimen of XC8, film-coated tablets, 10 mg for treatment of dry non-productive cough against acute respiratory infections.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

NCT05273619

Common Cold Acute Respiratory Infection Influenza, Human

COMPLETED PHASE3

Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections

NCT06379542

Acute Respiratory Infection

RECRUITING PHASE3

XC8 in the Treatment of Patients With Acute Respiratory Viral Infection

NCT03441373

Influenza Acute Respiratory Infection

COMPLETED PHASE2/PHASE3

Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers

NCT05558462

Influenza Respiratory Viral Infection

COMPLETED NA

A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

NCT05030324

Influenza Viral Respiratory Infection Acute Viral Upper Respiratory Infections

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Common Cold Acute Respiratory Infection Influenza, Human

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

XC8, film-coated tablets, 20 mg/day

Group Type EXPERIMENTAL

XC8, film-coated tablets, 20 mg/day

Intervention Type DRUG

20 mg/day (1 tablet twice a day)

XC8, film-coated tablets, 40 mg/day

Group Type EXPERIMENTAL

XC8, film-coated tablets, 40 mg/day

Intervention Type DRUG

40 mg/day (2 tablets twice a day)

XC8, film-coated tablets, 80 mg/day

Group Type EXPERIMENTAL

XC8, film-coated tablets, 80 mg/day

Intervention Type DRUG

80 mg/day (4 tablets twice a day)

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

1, 2, or 4 tablets twice a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

XC8, film-coated tablets, 20 mg/day

20 mg/day (1 tablet twice a day)

Intervention Type DRUG

XC8, film-coated tablets, 40 mg/day

40 mg/day (2 tablets twice a day)

Intervention Type DRUG

XC8, film-coated tablets, 80 mg/day

80 mg/day (4 tablets twice a day)

Intervention Type DRUG

Placebo

1, 2, or 4 tablets twice a day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signing and dating of the IPP informed consent form by the patient.
2. Women and men between the ages of 18 and 65 years, inclusive, at the time of signing the informed consent form.
3. Clinical diagnosis of acute respiratory viral infection of the upper respiratory tract (ICD-10 code J00-J06) or acute bronchitis (J20, J21 according to ICD-10).
4. Onset of disease symptoms no more than 3 days prior to screening.
5. Presence of a patient with a dry unproductive cough.
6. Frequency of cough episodes ≥10 in the past 24 h before the screening visit and randomization.
7. Cough frequency rated by the patient as 3-4 on the daytime cough section and 2-4 on the nighttime cough section of the Daytime and Nighttime Cough Scales.
8. Patient rating of cough severity on the DRS ≥ 4 points.
9. No indication for therapy due to BHSA infection at the time of study inclusion: negative rapid test for Group A β-haemolytic streptococcus.
10. For women of preserved reproductive potential, a negative pregnancy test and agreement to use approved contraceptive methods for the duration of study participation, beginning at visit 0, and for 3 weeks after the end of the study; for men, agreement to use approved contraceptive methods throughout the study participation period and for 3 weeks after the end of the study.

6. Taking any of the drugs of prohibited therapy, performing a prohibited procedure.
7. The necessity of prescribing prohibited concomitant therapy/procedures.
8. Pregnancy of the patient.
9. Patient's desire to stop participating in the study.
10. Lack of adequate cooperation of the patient with the doctor-researcher during the study.
11. Other protocol violations that are significant in the opinion of the physician-researcher.
12. Other administrative reasons.

Exclusion Criteria

1. Known or suspected hypersensitivity to the active ingredient or any of the excipients of the study drug/placebo.
2. Known or suspected hypersensitivity to acetylcysteine.
3. Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
4. Trauma (including open wounds in the mouth and erosive-desquamous lesions of the oral mucosa) and/or oropharyngeal burns, scarlet fever, rubella, measles, mumps at the time of screening or within 3 months prior to screening.
5. Acute obstructive laryngitis or suspected obstructive laryngitis.
6. Presence of signs of laryngeal stenosis (stridor, shortness of breath).
7. Exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (COPD).
8. Bronchial asthma, including a history.
9. History of tuberculosis.
10. History of pulmonary emphysema.
11. Acute or chronic pneumonia, or suspected pneumonia.
12. Condition after intubation.
13. Gastroesophageal reflux being the primary cause of cough (as judged by the investigating physician).
14. Allergic rhinitis as primary cause of cough (according to study physician).
15. Body temperature \> 39.0 °C.
16. Presence of at least one of the epidemic signs: return from a foreign trip 14 days prior to the onset of symptoms; presence of close contact in the past 14 days with a person under COVID-19 surveillance who has subsequently become ill; having close contact in the past 14 days with a person who has a laboratory-confirmed diagnosis of COVID-19; having occupational contacts with an individual with a suspected or confirmed case of COVID-19.
17. Positive result of laboratory testing for SARS-CoV-2 RNA using nucleic acid amplification techniques or SARS-CoV-2 antigen using immunochromatographic analysis at the time of screening.
18. The need for systemic antibiotic therapy and/or other drugs/procedures from the list of prohibited therapies/procedures.
19. Use of analgesics or antipyretics within 12 hours prior to screening.
20. Use of glucocorticosteroids, β-adrenoblockers, ACE inhibitors, theophylline drugs, expectorants, cough suppressants, anesthetics, anti-allergic drugs (leukotriene receptor antagonists, H1-histamine receptor blockers, sodium cromoglycate preparations), antiviral drugs, immunosuppressants, systemic antibacterial drugs for 7 days before screening.
21. History of smoking more than 10 pack/years (pack-years: number of cigarettes smoked per day multiplied by the number of years of smoking divided by 20).
22. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) levels ≥ 2.5 × highest normal value, serum bilirubin levels ≥ 1.5 × highest normal value.
23. Glomerular filtration rate (GFR) ≤ 60 ml/min.
24. History of cancer of the respiratory system.
25. History of other malignancies, except for patients who have not had the disease in the past 5 years, patients with fully cured basal cell carcinoma of the skin, or fully cured carcinoma in situ.
26. Serious cardiovascular disease at the time of screening or within 12 months prior to screening, including: New York Heart Association Class III or IV chronic heart failure, severe arrhythmias requiring treatment with antiarrhythmic drugs, unstable angina pectoris, myocardial infarction, heart and coronary artery surgery, transient ischemic attack or stroke, uncontrolled hypertension with systolic blood pressure \> 180 mm Hg Std. and diastolic blood pressure \>110 mmHg, pulmonary embolism.
27. Other severe, decompensated or unstable somatic diseases (any disease or condition that threatens the patient's life or worsens the patient's prognosis, or makes it impossible for the patient to participate in a clinical trial).
28. Patient's unwillingness or inability to comply with protocol procedures (in the opinion of the research physician).
29. Pregnancy or breastfeeding (for women).
30. Alcoholism, drug dependence, substance abuse history and/or at the time of screening.
31. A history of schizophrenia, schizoaffective disorder, bipolar disorder or other psychiatric pathology.
32. Participation in another clinical trial within 3 months prior to inclusion in the study.
33. Other conditions that, in the opinion of the investigating physician, preclude inclusion of the patient in the study.

Withdrawal Criteria:

1. Identification of a probable or confirmed case of COVID-19
2. Ineffectiveness of therapy - persistence or increased frequency of cough attacks ≥ 1 by visit 3 (day 8-9) compared to visit 1 (day 1).
3. AEs requiring withdrawal of study drug/placebo.
4. The occurrence of any disease or condition during the study that, in the opinion of the study physician, worsens the patient's prognosis and also makes it impossible for the patient to continue participating in the clinical trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No